BR112014008602B1 - Composição farmacêutica, recipiente vedado, inalador de dosagem medida, e, método para fabricação de uma composição farmacêutica - Google Patents

Composição farmacêutica, recipiente vedado, inalador de dosagem medida, e, método para fabricação de uma composição farmacêutica Download PDF

Info

Publication number
BR112014008602B1
BR112014008602B1 BR112014008602-8A BR112014008602A BR112014008602B1 BR 112014008602 B1 BR112014008602 B1 BR 112014008602B1 BR 112014008602 A BR112014008602 A BR 112014008602A BR 112014008602 B1 BR112014008602 B1 BR 112014008602B1
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
propellant
drug
oleic acid
weight
Prior art date
Application number
BR112014008602-8A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014008602A2 (pt
Inventor
Stuart Corr
Timothy James Noakes
Original Assignee
Mexichem Amanco Holding S.A. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mexichem Amanco Holding S.A. De C.V. filed Critical Mexichem Amanco Holding S.A. De C.V.
Publication of BR112014008602A2 publication Critical patent/BR112014008602A2/pt
Publication of BR112014008602B1 publication Critical patent/BR112014008602B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003—Adding propellants in fluid form to aerosol containers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014008602-8A 2011-10-12 2012-10-12 Composição farmacêutica, recipiente vedado, inalador de dosagem medida, e, método para fabricação de uma composição farmacêutica BR112014008602B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1117619.5A GB201117619D0 (en) 2011-10-12 2011-10-12 Compositions
GB1117619.5 2011-10-12
PCT/GB2012/052544 WO2013054137A1 (en) 2011-10-12 2012-10-12 Compositions comprising salbutamol sulphate

Publications (2)

Publication Number Publication Date
BR112014008602A2 BR112014008602A2 (pt) 2017-04-18
BR112014008602B1 true BR112014008602B1 (pt) 2022-05-24

Family

ID=45091931

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008602-8A BR112014008602B1 (pt) 2011-10-12 2012-10-12 Composição farmacêutica, recipiente vedado, inalador de dosagem medida, e, método para fabricação de uma composição farmacêutica

Country Status (12)

Country Link
US (2) US9517216B2 (cg-RX-API-DMAC7.html)
EP (1) EP2766006B1 (cg-RX-API-DMAC7.html)
JP (1) JP5894283B2 (cg-RX-API-DMAC7.html)
CN (1) CN103874489B (cg-RX-API-DMAC7.html)
AU (1) AU2012322455B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014008602B1 (cg-RX-API-DMAC7.html)
CA (1) CA2851026C (cg-RX-API-DMAC7.html)
ES (1) ES2556586T3 (cg-RX-API-DMAC7.html)
GB (1) GB201117619D0 (cg-RX-API-DMAC7.html)
MX (1) MX335944B (cg-RX-API-DMAC7.html)
WO (1) WO2013054137A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402321B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN112472689B (zh) * 2015-12-04 2023-01-17 墨西哥氟石股份公司 药物组合物
CN113288869A (zh) * 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
JP6781829B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
MY210122A (en) * 2016-09-19 2025-08-28 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3515425B1 (en) * 2016-09-19 2021-06-09 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising salmeterol
CN109789131B (zh) * 2016-09-19 2022-08-26 墨西哥氟石股份公司 药物组合物
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods
FR3130554B1 (fr) 2021-12-20 2024-10-18 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
FR3137830A1 (fr) 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
WO2024033941A1 (en) * 2022-08-10 2024-02-15 Cipla Limited A pharmaceutical composition of salbutamol and pharmaceutical green propellant
US20250017850A1 (en) * 2023-07-14 2025-01-16 Honeywell International Inc. Salbutamol delivery formulations, devices and methods
US20250152508A1 (en) * 2023-11-12 2025-05-15 Honeywell International Inc. Salbutamol delivery compositions, devices and methods
US12383516B1 (en) 2025-01-06 2025-08-12 Amphastar Pharmaceuticals, Inc. Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
DK0717987T3 (da) * 1991-12-18 2001-11-12 Minnesota Mining & Mfg Suspension-aerosol-formuleringer
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
JP4155594B2 (ja) 1994-12-22 2008-09-24 アストラゼネカ・アクチエボラーグ エアゾール製剤
MX9707862A (es) 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida para el propionato de fluticasona.
ATE248583T1 (de) 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ATE234604T1 (de) 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
GB2392164B (en) 1999-09-11 2004-04-07 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CN1559389A (zh) * 2004-03-05 2005-01-05 山东京卫制药有限公司 硫酸左旋沙丁胺醇气雾剂及其制备工艺
WO2006004646A1 (en) 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
CN101428010A (zh) * 2008-12-12 2009-05-13 国家纳米技术与工程研究院 一种硫酸沙丁胺醇细粉的制备方法
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process

Also Published As

Publication number Publication date
US9517216B2 (en) 2016-12-13
GB201117619D0 (en) 2011-11-23
MX2014004279A (es) 2014-05-28
CA2851026A1 (en) 2013-04-18
CN103874489A (zh) 2014-06-18
ES2556586T3 (es) 2016-01-19
JP5894283B2 (ja) 2016-03-23
AU2012322455A1 (en) 2014-04-17
AU2012322455B2 (en) 2015-07-02
WO2013054137A1 (en) 2013-04-18
EP2766006B1 (en) 2015-11-25
US20140230812A1 (en) 2014-08-21
MX335944B (es) 2016-01-04
ZA201402321B (en) 2015-03-25
US20170165367A1 (en) 2017-06-15
CA2851026C (en) 2016-01-05
JP2014528470A (ja) 2014-10-27
US10039828B2 (en) 2018-08-07
CN103874489B (zh) 2016-01-20
EP2766006A1 (en) 2014-08-20
BR112014008602A2 (pt) 2017-04-18

Similar Documents

Publication Publication Date Title
JP6931383B2 (ja) 薬学的組成物
US10039828B2 (en) Compositions comprising salbutamol sulphate
US9114164B2 (en) Compositions comprising salbutamol sulphate
AU2019201521B2 (en) Pharmaceutical composition
BR112013029202B1 (pt) Solução farmacêutica para administração usando um inalador de dose medida compreendendo dipropionato de beclometasona e/ou propionato de fluticasona, etanol e propelente de 1,1-difluoroetano, recipiente selado, inalador de dose medida, e, uso da composição
BR112015026053B1 (pt) Composição farmacêutica, recipiente vedado, inalador dosimetrado, uso de uma composição compreendendo um componente propelente, e, método para fabricação de uma composição farmacêutica
GB2554092A (en) Pharmaceutical composition
BR112018011269B1 (pt) Composição farmacêutica, e, métodos para aumentar o tempo de assentamento de uma composição farmacêutica, para estabilizar uma composição farmacêutica e para melhorar o desempenho de aerossolização

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/10/2012, OBSERVADAS AS CONDICOES LEGAIS